Company intelligence / Profile preview

Mendeli KABS

Saint-Hubert, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

MendeliKABS is a Canadian pharmaceutical company based in Saint-Hubert, Quebec, specializing in the development and commercialization of affordable treatments for rare (orphan) diseases. An affiliate of KABS Laboratories, the company leverages internal manufacturing capabilities to produce high-quality medications in compliance with international standards. Its lead product, MDK-Nitisinone (nitisinone), is a small molecule inhibitor of 4-hydroxyphenylpyruvate dioxygenase approved by Health Canada and the European Medicines Agency for the treatment of hereditary tyrosinemia type 1 (HT-1). MendeliKABS is committed to expanding access to life-saving orphan drugs through strategic partnerships and efficient production.

Therapeutic areas: Metabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

WEP Clinical

Beyond the preview

Go deeper on Mendeli KABS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mendeli KABS.

Explore the full profile